Annovis Bio Inc (ANVS)
NYSE:ANVS
Want to see ANVS full AI Analyst Report?
ANVS Stock Chart & Stats
$1.87
-$0.04(-0.79%)
At close: 4:00 PM EST
$1.87
-$0.04(-0.79%)
Day’s Range― - ―
52-Week Range$1.54 - $5.50
Previous CloseN/A
Volume368.97K
Average Volume (3M)1.25M
Market Cap
$71.03M
Enterprise Value$25.92M
Total Cash (Recent Filing)$14.22M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.70
Next Earnings
Aug 18, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.72
Shares Outstanding34,646,870
10 Day Avg. Volume868,587
30 Day Avg. Volume1,250,356
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)4.22
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap0.36
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.63
Forecast
1Y Price Target
$12.50Price Target Upside568.45% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.25
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial Progress And SafetySubstantial patient enrollment in the pivotal Alzheimer's Phase 3 trial, together with an independent safety review reporting no concerns, supports continued study momentum and investor confidence in trial conduct.
Efficacy Signals And Regulatory PotentialEarly efficacy signals and biomarker improvements observed in Alzheimer's and Parkinson's studies could underpin an initial regulatory filing and eventual label expansion if confirmed by pivotal results.
Financing / CapitalizationA financing extended the company's cash runway beyond the key Phase 3 data milestone for buntanetap, reducing funding pressure and supporting continued trial execution.
Bears Say
Clinical Timeline UncertaintyA revised timeline for the symptomatic readout delays availability of efficacy data, prolonging uncertainty for investors and extending the timeframe before potential regulatory decisions.
Financial Position And Dilution RiskA substantial operating loss and limited cash reserves indicate a likely need to raise additional capital to fund ongoing trials, creating potential dilution risk for existing shareholders.
Regulatory And Development RiskAlzheimer's disease is a high-risk therapeutic area, increasing development and regulatory uncertainty and amplifying the risk that trial outcomes may not lead to approval.
Annovis Bio News
ANVS FAQ
What was Annovis Bio Inc’s price range in the past 12 months?
Annovis Bio Inc lowest stock price was $1.54 and its highest was $5.50 in the past 12 months.
What is Annovis Bio Inc’s market cap?
Annovis Bio Inc’s market cap is $71.03M.
When is Annovis Bio Inc’s upcoming earnings report date?
Annovis Bio Inc’s upcoming earnings report date is Aug 18, 2026 which is in 89 days.
How were Annovis Bio Inc’s earnings last quarter?
Annovis Bio Inc released its earnings results on May 15, 2026. The company reported -$0.63 earnings per share for the quarter, missing the consensus estimate of -$0.395 by -$0.235.
Is Annovis Bio Inc overvalued?
According to Wall Street analysts Annovis Bio Inc’s price is currently Undervalued.
Does Annovis Bio Inc pay dividends?
Annovis Bio Inc does not currently pay dividends.
What is Annovis Bio Inc’s EPS estimate?
Annovis Bio Inc’s EPS estimate is -0.32.
How many shares outstanding does Annovis Bio Inc have?
Annovis Bio Inc has 34,646,870 shares outstanding.
What happened to Annovis Bio Inc’s price movement after its last earnings report?
Annovis Bio Inc reported an EPS of -$0.63 in its last earnings report, missing expectations of -$0.395. Following the earnings report the stock price went down -3.286%.
Which hedge fund is a major shareholder of Annovis Bio Inc?
Currently, no hedge funds are holding shares in ANVS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Annovis Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.50 (568.45% Upside)
$12.50 (568.45% Upside)
Blogger Sentiment
Bullish
ANVS Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 2.3%
Last 30 Days ▲ 2.3%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.67%
12-Months-Change
Fundamentals
Return on Equity
-318.08%
Trailing 12-Months
Asset Growth
-39.25%
Trailing 12-Months
Company Description
Annovis Bio Inc
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
ANVS Stock 12 Month Forecast
Average Price Target
$12.50
▲(568.45% Upside)
Technical Analysis
Whitehawk Therapeutics
―
Precision BioSciences
―
Greenwich LifeSciences
―
Acumen Pharmaceuticals
―
Coya Therapeutics, Inc.
―
Ownership Overview
13.70% Insiders
2.86% Mutual Funds
1.18% Other Institutional Investors
79.78% Public Companies and
Individual Investors